Amadea Britton

2.9k citations
23 papers · 1.5k · 6 hit papers · h-index 15

Impact in

  • Health top 1%
    • Vaccine Coverage and Hesitancy
    • SARS-CoV-2 and COVID-19 Research
    • COVID-19 Clinical Research Studies
    • Viral gastroenteritis research and epidemiology

Papers in

    • SARS-CoV-2 and COVID-19 Research 14
    • Viral gastroenteritis research and epidemiology 7
    • SARS-CoV-2 detection and testing 5
    • Respiratory viral infections research 11
    • Pneumonia and Respiratory Infections 6
    • Influenza Virus Research Studies 4

Amadea Britton

23 papers receiving 1.5k citations

Hit Papers

Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024 2024 · 80 citations
800+1+2Years since publication100200300400

Peers

Amadea Britton
Comparison fields: 5 of 92
  • Health 444
  • Infectious Diseases 968
  • Modeling and Simulation 190
  • Epidemiology 569
  • Microbiology 81
Replace Sharon Gray with:
Sharon Gray United States
Yi Luo United States
Farid Khan United States
Paige Marquez United States
Danielle Moulia United States
Simon Cottrell United Kingdom
Ned Lewis United States
Srinivas Rao Valluri United States
Carmit Rubin Israel
Matt D. T. Hitchings United States
Amadea Britton relative to Sharon Gray United States Sharon Gray's profile →
Citations per field
00.5×
Sharon Gray · 1×
Citations per year

Countries citing papers authored by Amadea Britton

Since Specialization
Citations

This map shows the geographic impact of Amadea Britton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amadea Britton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amadea Britton more than expected).

Fields of papers citing papers by Amadea Britton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amadea Britton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amadea Britton. The network helps show where Amadea Britton may publish in the future.

Co-authors

The 25 scholars most cited alongside Amadea Britton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Amadea Britton Line = papers co-authored together Amadea Britton links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
Hit paper breakdown →
2022403
2
Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
Hit paper breakdown →
2022223
3
Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
Hit paper breakdown →
2023172
4 2021104
5 202288
6 202288
7
Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024
Hit paper breakdown →
202480
8
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023
Hit paper breakdown →
202376
9
Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
Hit paper breakdown →
202467
10 202259
11 202334
12 202326
13 202422
14 202221
15 202320
16 202311
17 20249
18 20159
19 20237
20 19867

About Amadea Britton

Amadea Britton is a scholar working on Infectious Diseases, Epidemiology, Health, Public Health, Environmental and Occupational Health and Modeling and Simulation, having authored 23 papers that have together received 1.5k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (14 papers), Respiratory viral infections research (11 papers), Viral gastroenteritis research and epidemiology (7 papers), Pneumonia and Respiratory Infections (6 papers), SARS-CoV-2 detection and testing (5 papers), Influenza Virus Research Studies (4 papers), Vaccine Coverage and Hesitancy (4 papers) and COVID-19 epidemiological studies (2 papers). The work is most often cited by research in Health (444 citations), Infectious Diseases (968 citations), Modeling and Simulation (190 citations), Epidemiology (569 citations) and Microbiology (81 citations). Amadea Britton has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include Katherine E. Fleming-Dutra, Zachary Smith, Jennifer R. Verani, Gordana Derado, Nong Shang, Emma K. Accorsi, Stephanie J. Schrag, Joseph D. Miller, Sarah S. Long and H. Keipp Talbot. Their work appears in journals such as MMWR Morbidity and Mortality Weekly Report, JAMA, Vaccine, Open Forum Infectious Diseases and Clinical Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact